The high clinical efficacy of IL‐17 and IL‐23‐targeted antibody therapies underscores the importance of these immune cells in psoriasis pathogenesis [13, 14, 15, 16, 17, 18, 19]. This evidence concerns the gene IL17A and psoriasis.